YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
TORONTO, Oct. 1, 2026 /CNW/ -- HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the "Board"), effective today. Th…
The GA-Courtenay Special Situations Fund is an investment fund managed by Green Ash Partners. The fund focuses on special situations and high-growth equities. You can download the July letter here. The fund reported a 13.8% decline in July…
ImmunityBio Inc. (NASDAQ:IBRX) saw its share price jump by 9.94 percent on Tuesday to finish at $9.29 apiece following a high-profile meeting between its founder, Dr. Patrick Soon-Shiong, and Turkish President Recep Tayyip Erdogan, fueling…
[Scientists inside a laboratory] Hinterhaus Productions The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease…
ImmunityBio IBRX shares soared 7% in the last trading session to close at $8.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.7% loss over the past four we…
Nant Capital's investment of up to $22.3 million in a PIPE into PDS Biotech, along with Patrick Soon Shiong's new board seat there, pushed ImmunityBio (NasdaqGS:IBRX) up 6% on Monday and sharpened focus on his broader immunotherapy plans.…
PDS Biotechnology Corporation Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PD…
A month has gone by since the last earnings report for Qiagen (QGEN). Shares have added about 5.1% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its…
Dr. Kim will advise on international partnerships and global access initiatives through the newly formed Office of the Executive Chairman CULVER CITY, Calif., August 10, 2026--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. ImmunityBio stock has delivered a very strong 321.9% return over the past three years, yet current…
After soaring by as much as 21.58 percent on Thursday, Caris Life Sciences Inc. (NASDAQ:CAI) heads into the next trading session with investors focused less on a stellar earnings performance and more on whether it can sustain its momentum…
In the past week, ImmunityBio, Inc. received marketing authorization in the United Arab Emirates for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, while reporting second-quart…
ImmunityBio IBRX reported an adjusted loss of 8 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The loss improved 20% compared with the year-ago period's loss of 10 cents. Tot…
ImmunityBio (IBRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.1 per share a year ago. These figures are adjusted for non-recurring items. This qua…
Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially from Q1 2026, marking the eighth consecutive quarter of sequential revenue growth since the commercial launch of ANKTIVA®, driven by continued adoptio…
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.4 per share a year ago. These figures are adjusted for non-recurring it…
The UAE authorization further expands ANKTIVA's global regulatory footprint to 34 countries. The BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) authorization is the first worldwide to span the full spectrum of BCG-unresponsive…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. ImmunityBio (IBRX) is back in focus after its stock surged 282.7% year to date, as investors weigh speculation around Anktiva's rol…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. ImmunityBio's stock has surged 282.7% year to date, yet its overall valuation checks sit at a mixed 3 out of 6. This leaves…
ImmunityBio IBRX shares soared 11.8% in the last trading session to close at $8.71. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.9% gain over the past four…
ImmunityBio, Inc. (NASDAQ:IBRX) was among the stocks on which Jim Cramer commented, as he emphasized that SpaceX investors are betting on Elon Musk rather than the company's earnings. When a caller mentioned that, as per their observation,…
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 10 Best Performing Growth Stocks So Far in 2026. On June 1, ImmunityBio, Inc. (NASDAQ:IBRX) reported that it presented two research posters and one online publication at the American Society of…
Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated…
ImmunityBio Inc. (NASDAQ:IBRX) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 19, Immunitybio Inc. (NASDAQ:IBRX) confirmed the US Food and Drug Administration accepted for review the supplemental Biologics Licen…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unres…
Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC) CULVER CITY, Calif., June 01, 2026--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stag…
ImmunityBio IBRX is trying to turn a persistent bottleneck in bladder cancer care into a durable demand driver. The long-running U.S. Bacillus Calmette-Guérin (BCG) shortage has created a structural “pull” for regimens that can improve tre…
ImmunityBio IBRX enters the post-earnings stretch with the stock at $7.72 (as of May 28, 2026) and a six to12 month price target of $8.25. After a 289.9% year-to-date surge, the setup is less about “what’s next” and more about what has alr…
ImmunityBio IBRX is building a portfolio of immunotherapies designed to activate both innate and adaptive immunity in cancer and infectious diseases. Its Cancer BioShield platform centers on Anktiva (nogapendekin alfa inbakicept), an inter…
ImmunityBio Inc. (NASDAQ:IBRX) is one of the best mid cap stocks to buy with highest upside potential. On May 22, ImmunityBio recently presented a health economic analysis at ISPOR 2026 demonstrating that ANKTIVA combined with BCG provides…
In May 2026, ImmunityBio reported that the FDA accepted for review its supplemental Biologics License Application for ANKTIVA plus BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with papillary disease, setting a PDUFA act…
ImmunityBio Inc. (NASDAQ:IBRX) is one of the best momentum stocks to buy according to analysts. ImmunityBio Inc. (NASDAQ:IBRX) announced on May 19 that the U.S. Food and Drug Administration accepted for review the supplemental Biologics Li…
LOS ANGELES, May 26, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dead…
NEW YORK, May 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the…
SAN FRANCISCO, May 25, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026…
LOS ANGELES, May 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for vio…